Clinical Trial Update: Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on the 13-valent pneumococcal conjugate vaccine (Prevnar 13) in infants; the study completed and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Vaccines, Pneumococcal | Phase 3 | Status: COMPLETED | Results posted: 2013-02-22